论文部分内容阅读
目的探究新活素用于慢性心力衰竭治疗中的价值。方法 64例慢性心力衰竭患者,随机分为对照组和观察组,每组32例。对照组患者给予常规抗心力衰竭治疗,观察组患者在此基础上加用新活素治疗,对比两组患者的活动耐力、N末端脑钠肽前体(NT-proBNP)、尿量、心功能指标[左室射血分数(LVEF)]等。结果观察组的治疗总有效率为93.75%,明显高于对照组的75.00%(P<0.05)。观察组患者治疗后的6 min步行试验长度和尿量优于对照组,且血浆NT-proBNP水平低于对照组,LVEF水平高于对照组(P<0.05)。结论新活素治疗慢性心力衰竭效果确切,有助于促进患者心功能的恢复,临床症状的缓解,提高患者的生活质量,值得推广。
Objective To explore the value of new activin in the treatment of chronic heart failure. Methods 64 patients with chronic heart failure were randomly divided into control group and observation group, 32 cases in each group. Patients in the control group were treated with conventional anti-heart failure. Patients in the observation group were treated with neomycin on the basis of these tests. Activity endurance, N-terminal pro-brain natriuretic peptide (NT-proBNP), urine output, heart function Indicators [left ventricular ejection fraction (LVEF)] and so on. Results The total effective rate of the observation group was 93.75%, which was significantly higher than that of the control group (75.00%, P <0.05). The length of 6-min walking test and urine output in the observation group were better than those in the control group. The plasma NT-proBNP level was lower than that of the control group, and the LVEF level was higher in the observation group than in the control group (P <0.05). Conclusion The new activin in the treatment of chronic heart failure has the exact effect, which is helpful to promote the recovery of cardiac function, alleviate the clinical symptoms and improve the quality of life of patients. It is worth popularizing.